Literature DB >> 15486068

Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.

Berthold Hoppe1, Farzaneh Tolou, Hartmut Radtke, Holger Kiesewetter, Thomas Dörner, Abdulgabar Salama.   

Abstract

The factor VII-activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess FSAP Marburg I's role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = .014) or idiopathic VTE (12 of 103 patients, 11.7%, P = .002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio, 3.5; 95% confidence interval [CI], 1.2-10.0) and idiopathic VTE (odds ratio, 6.2; 95% CI, 2.0-18.9).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486068     DOI: 10.1182/blood-2004-08-3328

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls.

Authors:  Laure Cazabat; Aglae Terray; Philippe de Mazancourt; Jacques Ropers; Lionel Groussin; Marie-Laure Raffin-Sanson
Journal:  Eur Thyroid J       Date:  2017-06-23

2.  Whole-exome sequencing in evaluation of patients with venous thromboembolism.

Authors:  Eun-Ju Lee; Daniel J Dykas; Andrew D Leavitt; Rodney M Camire; Eduard Ebberink; Pablo García de Frutos; Kavitha Gnanasambandan; Sean X Gu; James A Huntington; Steven R Lentz; Koen Mertens; Christopher R Parish; Alireza R Rezaie; Peter P Sayeski; Caroline Cromwell; Noffar Bar; Stephanie Halene; Natalia Neparidze; Terri L Parker; Adrienne J Burns; Anne Dumont; Xiaopan Yao; Cassius Iyad Ochoa Chaar; Jean M Connors; Allen E Bale; Alfred Ian Lee
Journal:  Blood Adv       Date:  2017-06-29

3.  Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor.

Authors:  Sandip M Kanse; Paul J Declerck; Wolfram Ruf; George Broze; Michael Etscheid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-23       Impact factor: 8.311

4.  A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding.

Authors:  Boran Altincicek; Aya Shibamiya; Heidi Trusheim; Eleni Tzima; Michael Niepmann; Dietmar Linder; Klaus T Preissner; Sandip M Kanse
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

5.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

6.  Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation.

Authors:  Aya Shibamiya; Lars Muhl; Susanne Tannert-Otto; Klaus T Preissner; Sandip M Kanse
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

7.  Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.

Authors:  Sudheer Kumar Gara; Li Jia; Maria J Merino; Sunita K Agarwal; Lisa Zhang; Maggie Cam; Dhaval Patel; Electron Kebebew
Journal:  N Engl J Med       Date:  2015-07-30       Impact factor: 91.245

8.  Marburg I Polymorphism (G511E) in Adults with Deep Vein Thrombosis.

Authors:  Narender Kumar; Archana Sundaram; Neetu Rani; Jasmina Ahluwalia; Reena Das; Neelam Varma; Vikas Suri; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-12       Impact factor: 0.900

9.  The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer.

Authors:  Ruta Sahasrabudhe; Jacob Stultz; John Williamson; Paul Lott; Ana Estrada; Mabel Bohorquez; Claire Palles; Guadalupe Polanco-Echeverry; Emma Jaeger; Lynn Martin; Maria Magdalena Echeverry; Ian Tomlinson; Luis G Carvajal-Carmona
Journal:  J Clin Endocrinol Metab       Date:  2015-12-21       Impact factor: 5.958

10.  Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality.

Authors:  Stella Trompet; Douwe Pons; Sandip M Kanse; Anton J M de Craen; M Arfan Ikram; Jeffrey J W Verschuren; Aeilko H Zwinderman; Pieter A F M Doevendans; René A Tio; Robbert J de Winter; P Eline Slagboom; Rudi G J Westendorp; J Wouter Jukema
Journal:  Stroke Res Treat       Date:  2011-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.